578P - Adjuvant Oxaliplatin Dose and Dose Reductions are Associated with Severity of Peripheral Neuropathy Among Colorectal Cancer Survivors: Results from the Population-Based Profiles Registry

Abstract

ABSTRACT Aim: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of oxaliplatin which can negatively influence quality of life. We aimed to study the influence of cumulative dose, dose schedule and dose reductions of adjuvant oxaliplatin on long-term severity and prevalence of CIPN among colorectal cancer (CRC) survivors. Methods: A total of 188 patients, diagnosed with CRC between 2000 and 2009 who underwent adjuvant treatment with oxaliplatin, were included. Patients were identified by the Eindhoven Cancer Registry. All patients completed the EORTC QLQ-CIPN20 2-11 years after diagnosis. Data on oxaliplatin administration and acute neuropathy during treatment were extracted from the medical files. Results: Oxaliplatin was given for a median 6 cycles (range 1-12) at a mean cumulative dose of 680 mg/m2 (SD 265). Patients who received cumulative oxaliplatin dose of ≥842 mg/m2 had a significantly worse EORTC QLQ-CIPN20 sensory score compared to those who received a low cumulative dose of Conclusions: Cumulative dose of oxaliplatin is associated with long-term CIPN in CRC survivors. The risk of developing long-term CIPN could only be reduced by decreasing the cumulative dose of oxaliplatin early in the treatment period. Future studies should focus on identifying patients who are at risk of developing CIPN. Disclosure: All authors have declared no conflicts of interest.